Pharmacology, physiology, and mechanisms of incretin hormone action

Cell Metabolism

Volumn 17, Issue 6, 2013, Pages 819-837

  Campbell, Jonathan E ^a   Drucker, Daniel J ^a  

^a MOUNT SINAI HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AC 3174; ALANINE AMINOTRANSFERASE; BETA CATENIN; EXENDIN 4; GASTRIC INHIBITORY POLYPEPTIDE; GASTRIN; GLIMEPIRIDE; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; INSULIN; INSULIN GLARGINE; MESSENGER RNA; METFORMIN; MITOGEN ACTIVATED PROTEIN KINASE 3; OXYNTOMODULIN; PIOGLITAZONE; UNCLASSIFIED DRUG; WNT4 PROTEIN;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; APPETITE; BODY MASS; BODY WEIGHT; BROWN ADIPOSE TISSUE; CELL PROLIFERATION; CELL SURVIVAL; DOWN REGULATION; ENZYME PHOSPHORYLATION; FATTY LIVER; GASTROINTESTINAL MOTILITY; GLYCEMIC CONTROL; HORMONE ACTION; HUMAN; HYPERGLYCEMIA; HYPERINSULINEMIA; IMMUNOREACTIVITY; IN VIVO STUDY; INSULIN SENSITIVITY; LIPID METABOLISM; LIVER CELL; NONHUMAN; PANCREAS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; WESTERN BLOTTING;

ANIMALS; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON-LIKE PEPTIDE 1; HUMANS; INCRETINS; ISLETS OF LANGERHANS; MICE; RECEPTORS, GASTROINTESTINAL HORMONE; SIGNAL TRANSDUCTION;

EID: 84878808238     PISSN: 15504131     EISSN: 19327420     Source Type: Journal    
DOI: 10.1016/j.cmet.2013.04.008     Document Type: Review

References (150)

1. T. Abbas, E. Faivre, and C. Hölscher Impairment of synaptic plasticity and memory formation in GLP-1 receptor KO mice: Interaction between type 2 diabetes and Alzheimer's disease Behav. Brain Res. 205 2009 265 271
2. T. Ahern, A.M. Tobin, M. Corrigan, A. Hogan, C. Sweeney, B. Kirby, and D. O'Shea Glucagon-like peptide-1 analogue therapy for psoriasis patients with obesity and type 2 diabetes: a prospective cohort study J. Eur. Acad. Dermatol. Venereol. 2012 10.1111/j.1468-3083.2012.04609.x Published online June 13, 2012
3. E. Ahlqvist, P. Osmark, T. Kuulasmaa, K. Pilgaard, B. Omar, C. Brøns, O. Kotova, A.V. Zetterqvist, A. Stancáková, and A. Jonsson A link between GIP and osteopontin in adipose tissue and insulin resistance Diabetes 2013 10.2337/db12-0976 Published online January 24, 2013
4. M.C. Althage, E.L. Ford, S. Wang, P. Tso, K.S. Polonsky, and B.M. Wice Targeted ablation of glucose-dependent insulinotropic polypeptide-producing cells in transgenic mice reduces obesity and insulin resistance induced by a high fat diet J. Biol. Chem. 283 2008 18365 18376
5. M. Asmar, L. Simonsen, S. Madsbad, B. Stallknecht, J.J. Holst, and J. Bülow Glucose-dependent insulinotropic polypeptide may enhance fatty acid re-esterification in subcutaneous abdominal adipose tissue in lean humans Diabetes 59 2010 2160 2163
6. A. Astrup, S. Rössner, L. Van Gaal, A. Rissanen, L. Niskanen, M. Al Hakim, J. Madsen, M.F. Rasmussen, M.E. Lean NN8022-1807 Study Group Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study Lancet 374 2009 1606 1616
7. J.E. Ayala, D.P. Bracy, F.D. James, B.M. Julien, D.H. Wasserman, and D.J. Drucker The glucagon-like peptide-1 receptor regulates endogenous glucose production and muscle glucose uptake independent of its incretin action Endocrinology 150 2009 1155 1164
8. H.E. Bates, J.E. Campbell, J.R. Ussher, L.L. Baggio, A. Maida, Y. Seino, and D.J. Drucker Gipr is essential for adrenocortical steroidogenesis; however, corticosterone deficiency does not mediate the favorable metabolic phenotype of Gipr(-/-) mice Diabetes 61 2012 40 48
9. E. Bertin, P. Arner, J. Bolinder, and E. Hagström-Toft Action of glucagon and glucagon-like peptide-1-(7-36) amide on lipolysis in human subcutaneous adipose tissue and skeletal muscle in vivo J. Clin. Endocrinol. Metab. 86 2001 1229 1234
10. L. Bjerre Knudsen, L.W. Madsen, S. Andersen, K. Almholt, A.S. de Boer, D.J. Drucker, C. Gotfredsen, F.L. Egerod, A.C. Hegelund, and H. Jacobsen Glucagon-like Peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation Endocrinology 151 2010 1473 1486
11. T.R. Bomfim, L. Forny-Germano, L.B. Sathler, J. Brito-Moreira, J.C. Houzel, H. Decker, M.A. Silverman, H. Kazi, H.M. Melo, and P.L. McClean An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer's disease- associated Aβ oligomers J. Clin. Invest. 122 2012 1339 1353
12. M. Boutant, O.H. Ramos, C. Tourrel-Cuzin, J. Movassat, A. Ilias, D. Vallois, J. Planchais, J.P. Pégorier, F. Schuit, and P.X. Petit COUP-TFII controls mouse pancreatic β-cell mass through GLP-1-β-catenin signaling pathways PLoS ONE 7 2012 e30847
13. D. Bradley, C. Conte, B. Mittendorfer, J.C. Eagon, J.E. Varela, E. Fabbrini, A. Gastaldelli, K.T. Chambers, X. Su, and A. Okunade Gastric bypass and banding equally improve insulin sensitivity and β cell function J. Clin. Invest. 122 2012 4667 4674
14. M.C. Bunck, A. Cornér, B. Eliasson, R.J. Heine, R.M. Shaginian, M.R. Taskinen, U. Smith, H. Yki-Järvinen, and M. Diamant Effects of exenatide on measures of β-cell function after 3 years in metformin-treated patients with type 2 diabetes Diabetes Care 34 2011 2041 2047
15. R. Burcelin, A. Da Costa, D. Drucker, and B. Thorens Glucose competence of the hepatoportal vein sensor requires the presence of an activated glucagon-like peptide-1 receptor Diabetes 50 2001 1720 1728
16. M.A. Burmeister, T. Ferre, J.E. Ayala, E.M. King, R.M. Holt, and J.E. Ayala Acute activation of central GLP-1 receptors enhances hepatic insulin action and insulin secretion in high-fat-fed, insulin resistant mice Am. J. Physiol. Endocrinol. Metab. 302 2012 E334 E343
17. M.A. Burmeister, J.E. Ayala, D.J. Drucker, and J.E. Ayala Central glucagon-like peptide 1 receptor-induced anorexia requires glucose metabolism-mediated suppression of AMPK and is impaired by central fructose Am. J. Physiol. Endocrinol. Metab. 304 2013 E677 E685
18. C. Cabou, G. Campistron, N. Marsollier, C. Leloup, C. Cruciani-Guglielmacci, L. Pénicaud, D.J. Drucker, C. Magnan, and R. Burcelin Brain glucagon-like peptide-1 regulates arterial blood flow, heart rate, and insulin sensitivity Diabetes 57 2008 2577 2587
19. C. Cabou, C. Vachoux, G. Campistron, D.J. Drucker, and R. Burcelin Brain GLP-1 signaling regulates femoral artery blood flow and insulin sensitivity through hypothalamic PKC-δ Diabetes 60 2011 2245 2256
20. C.W. Chia, O.D. Carlson, W. Kim, Y.K. Shin, C.P. Charles, H.S. Kim, D.L. Melvin, and J.M. Egan Exogenous glucose-dependent insulinotropic polypeptide worsens post prandial hyperglycemia in type 2 diabetes Diabetes 58 2009 1342 1349
21. M. Cornu, J.Y. Yang, E. Jaccard, C. Poussin, C. Widmann, and B. Thorens Glucagon-like peptide-1 protects beta-cells against apoptosis by increasing the activity of an IGF-2/IGF-1 receptor autocrine loop Diabetes 58 2009 1816 1825
22. M. Cornu, H. Modi, D. Kawamori, R.N. Kulkarni, M. Joffraud, and B. Thorens Glucagon-like peptide-1 increases beta-cell glucose competence and proliferation by translational induction of insulin-like growth factor-1 receptor expression J. Biol. Chem. 285 2010 10538 10545
23. R.O. Crajoinas, F.T. Oricchio, T.D. Pessoa, B.P. Pacheco, L.M. Lessa, G. Malnic, and A.C. Girardi Mechanisms mediating the diuretic and natriuretic actions of the incretin hormone glucagon-like peptide-1 Am. J. Physiol. Renal Physiol. 301 2011 F355 F363
24. G. da Silva Xavier, A. Mondragon, G. Sun, L. Chen, J.A. McGinty, P.M. French, and G.A. Rutter Abnormal glucose tolerance and insulin secretion in pancreas-specific Tcf7l2-null mice Diabetologia 55 2012 2667 2676
25. J.W. Day, N. Ottaway, J.T. Patterson, V. Gelfanov, D. Smiley, J. Gidda, H. Findeisen, D. Bruemmer, D.J. Drucker, and N. Chaudhary A new glucagon and GLP-1 co-agonist eliminates obesity in rodents Nat. Chem. Biol. 5 2009 749 757
26. J. de Heer, and J.J. Holst Sulfonylurea compounds uncouple the glucose dependence of the insulinotropic effect of glucagon-like peptide 1 Diabetes 56 2007 438 443
27. J. de Heer, C. Rasmussen, D.H. Coy, and J.J. Holst Glucagon-like peptide-1, but not glucose-dependent insulinotropic peptide, inhibits glucagon secretion via somatostatin (receptor subtype 2) in the perfused rat pancreas Diabetologia 51 2008 2263 2270
28. E. Diakogiannaki, F.M. Gribble, and F. Reimann Nutrient detection by incretin hormone secreting cells Physiol. Behav. 106 2012 387 393
29. X. Ding, N.K. Saxena, S. Lin, N.A. Gupta, and F.A. Anania Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice Hepatology 43 2006 173 181
30. D.D. Dore, J.D. Seeger, and K. Arnold Chan Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide Curr. Med. Res. Opin. 25 2009 1019 1027
31. D.J. Drucker Glucagon-like peptides: regulators of cell proliferation, differentiation, and apoptosis Mol. Endocrinol. 17 2003 161 171
32. D.J. Drucker The biology of incretin hormones Cell Metab. 3 2006 153 165
33. D.J. Drucker Incretin-based therapy and the quest for sustained improvements in β-cell health Diabetes Care 34 2011 2133 2135
34. A.M. Duffy, and C. Hölscher The incretin analogue D-Ala(2)GIP reduces plaque load, astrogliosis and oxidative stress in an APP/PS1 mouse model of Alzheimer's disease Neuroscience 228 2013 294 300
35. J. Dupré, M.T. Behme, and T.J. McDonald Exendin-4 normalized postcibal glycemic excursions in type 1 diabetes J. Clin. Endocrinol. Metab. 89 2004 3469 3473
36. M.J. During, L. Cao, D.S. Zuzga, J.S. Francis, H.L. Fitzsimons, X. Jiao, R.J. Bland, M. Klugmann, W.A. Banks, D.J. Drucker, and C.N. Haile Glucagon-like peptide-1 receptor is involved in learning and neuroprotection Nat. Med. 9 2003 1173 1179
37. H. Ellingsgaard, I. Hauselmann, B. Schuler, A.M. Habib, L.L. Baggio, D.T. Meier, E. Eppler, K. Bouzakri, S. Wueest, and Y.D. Muller Interleukin-6 enhances insulin secretion by increasing glucagon-like peptide-1 secretion from L cells and alpha cells Nat. Med. 17 2011 1481 1489
38. E. Faivre, V.A. Gault, B. Thorens, and C. Hölscher Glucose-dependent insulinotropic polypeptide receptor knockout mice are impaired in learning, synaptic plasticity, and neurogenesis J. Neurophysiol. 105 2011 1574 1580
39. R.N. Faradji, T. Tharavanij, S. Messinger, T. Froud, A. Pileggi, K. Monroy, D. Mineo, D.A. Baidal, P. Cure, and G. Ponte Long-term insulin independence and improvement in insulin secretion after supplemental islet infusion under exenatide and etanercept Transplantation 86 2008 1658 1665
40. C.P. Figueiredo, V.L. Antunes, E.L. Moreira, N. de Mello, R. Medeiros, G. Di Giunta, B. Lobão-Soares, M. Linhares, K. Lin, and T.L. Mazzuco Glucose-dependent insulinotropic peptide receptor expression in the hippocampus and neocortex of mesial temporal lobe epilepsy patients and rats undergoing pilocarpine induced status epilepticus Peptides 32 2011 781 789
41. G. Flock, L.L. Baggio, C. Longuet, and D.J. Drucker Incretin receptors for glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide are essential for the sustained metabolic actions of vildagliptin in mice Diabetes 56 2007 3006 3013
42. Y. Fujita, R.D. Wideman, A. Asadi, G.K. Yang, R. Baker, T. Webber, T. Zhang, R. Wang, Z. Ao, and G.L. Warnock Glucose-dependent insulinotropic polypeptide is expressed in pancreatic islet alpha-cells and promotes insulin secretion Gastroenterology 138 2010 1966 1975
43. A. Fukami, Y. Seino, N. Ozaki, M. Yamamoto, C. Sugiyama, E. Sakamoto-Miura, T. Himeno, Y. Takagishi, S. Tsunekawa, and S. Ali Ectopic expression of GIP in pancreatic β-cells maintains enhanced insulin secretion in mice with complete absence of proglucagon-derived peptides Diabetes 62 2013 510 518
44. B. Gallwitz, J. Guzman, F. Dotta, B. Guerci, R. Simó, B.R. Basson, A. Festa, J. Kiljański, H. Sapin, M. Trautmann, and G. Schernthaner Exenatide twice daily versus glimepiride for prevention of glycaemic deterioration in patients with type 2 diabetes with metformin failure (EUREXA): an open-label, randomised controlled trial Lancet 379 2012 2270 2278
45. A. Garber, R.R. Henry, R. Ratner, P. Hale, C.T. Chang, B. Bode LEAD-3 (Mono) Study Group Liraglutide, a once-daily human glucagon-like peptide 1 analogue, provides sustained improvements in glycaemic control and weight for 2 years as monotherapy compared with glimepiride in patients with type 2 diabetes Diabetes Obes. Metab. 13 2011 348 356
46. R. Garg, W. Chen, and M. Pendergrass Acute pancreatitis in type 2 diabetes treated with exenatide or sitagliptin: a retrospective observational pharmacy claims analysis Diabetes Care 33 2010 2349 2354
47. V.A. Gault, and C. Hölscher GLP-1 agonists facilitate hippocampal LTP and reverse the impairment of LTP induced by beta-amyloid Eur. J. Pharmacol. 587 2008 112 117
48. V.A. Gault, and C. Hölscher Protease-resistant glucose-dependent insulinotropic polypeptide agonists facilitate hippocampal LTP and reverse the impairment of LTP induced by beta-amyloid J. Neurophysiol. 99 2008 1590 1595
49. M. Gejl, L. Egefjord, S. Lerche, K. Vang, B.M. Bibby, J.J. Holst, A. Mengel, N. Møller, J. Rungby, B. Brock, and A. Gjedde Glucagon-like peptide-1 decreases intracerebral glucose content by activating hexokinase and changing glucose clearance during hyperglycemia J. Cereb. Blood Flow Metab. 32 2012 2146 2152
50. B. Gier, A.V. Matveyenko, D. Kirakossian, D. Dawson, S.M. Dry, and P.C. Butler Chronic GLP-1 receptor activation by exendin-4 induces expansion of pancreatic duct glands in rats and accelerates formation of dysplastic lesions and chronic pancreatitis in the Kras(G12D) mouse model Diabetes 61 2012 1250 1262
51. O. Gögebakan, J. Andres, K. Biedasek, K. Mai, P. Kühnen, H. Krude, F. Isken, N. Rudovich, M.A. Osterhoff, and U. Kintscher Glucose-dependent insulinotropic polypeptide reduces fat-specific expression and activity of 11β-hydroxysteroid dehydrogenase type 1 and inhibits release of free fatty acids Diabetes 61 2012 292 300
52. S.F. Grant, G. Thorleifsson, I. Reynisdottir, R. Benediktsson, A. Manolescu, J. Sainz, A. Helgason, H. Stefansson, V. Emilsson, and A. Helgadottir Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes Nat. Genet. 38 2006 320 323
53. D. Gupta, M. Peshavaria, N. Monga, T.L. Jetton, and J.L. Leahy Physiologic and pharmacologic modulation of glucose-dependent insulinotropic polypeptide (GIP) receptor expression in beta-cells by peroxisome proliferator-activated receptor (PPAR)-gamma signaling: possible mechanism for the GIP resistance in type 2 diabetes Diabetes 59 2010 1445 1450
54. M.K. Gutniak, L. Juntti-Berggren, P.M. Hellström, A. Guenifi, J.J. Holst, and S. Efendic Glucagon-like peptide I enhances the insulinotropic effect of glibenclamide in NIDDM patients and in the perfused rat pancreas Diabetes Care 19 1996 857 863
55. J.P. Gutzwiller, S. Tschopp, A. Bock, C.E. Zehnder, A.R. Huber, M. Kreyenbuehl, H. Gutmann, J. Drewe, C. Henzen, B. Goeke, and C. Beglinger Glucagon-like peptide 1 induces natriuresis in healthy subjects and in insulin-resistant obese men J. Clin. Endocrinol. Metab. 89 2004 3055 3061
56. A.M. Habib, P. Richards, L.S. Cairns, G.J. Rogers, C.A. Bannon, H.E. Parker, T.C. Morley, G.S. Yeo, F. Reimann, and F.M. Gribble Overlap of endocrine hormone expression in the mouse intestine revealed by transcriptional profiling and flow cytometry Endocrinology 153 2012 3054 3065
57. I. Hadjiyanni, L.L. Baggio, P. Poussier, and D.J. Drucker Exendin-4 modulates diabetes onset in nonobese diabetic mice Endocrinology 149 2008 1338 1349
58. I. Hadjiyanni, K.A. Siminovitch, J.S. Danska, and D.J. Drucker Glucagon-like peptide-1 receptor signalling selectively regulates murine lymphocyte proliferation and maintenance of peripheral regulatory T cells Diabetologia 53 2010 730 740
59. T. Hansotia, A. Maida, G. Flock, Y. Yamada, K. Tsukiyama, Y. Seino, and D.J. Drucker Extrapancreatic incretin receptors modulate glucose homeostasis, body weight, and energy expenditure J. Clin. Invest. 117 2007 143 152
60. L. Hegedüs, A.C. Moses, M. Zdravkovic, T. Le Thi, and G.H. Daniels GLP-1 and calcitonin concentration in humans: lack of evidence of calcitonin release from sequential screening in over 5000 subjects with type 2 diabetes or nondiabetic obese subjects treated with the human GLP-1 analog, liraglutide J. Clin. Endocrinol. Metab. 96 2011 853 860
61. C. Heller, M.C. Kühn, B. Mülders-Opgenoorth, M. Schott, H.S. Willenberg, W.A. Scherbaum, and S. Schinner Exendin-4 upregulates the expression of Wnt-4, a novel regulator of pancreatic β-cell proliferation Am. J. Physiol. Endocrinol. Metab. 301 2011 E864 E872
62. D.B. Henriksen, P. Alexandersen, N.H. Bjarnason, T. Vilsbøll, B. Hartmann, E.E. Henriksen, I. Byrjalsen, T. Krarup, J.J. Holst, and C. Christiansen Role of gastrointestinal hormones in postprandial reduction of bone resorption J. Bone Miner. Res. 18 2003 2180 2189
63. A.E. Hogan, A.M. Tobin, T. Ahern, M.A. Corrigan, G. Gaoatswe, R. Jackson, V. O'Reilly, L. Lynch, D.G. Doherty, and P.N. Moynagh Glucagon-like peptide-1 (GLP-1) and the regulation of human invariant natural killer T cells: lessons from obesity, diabetes and psoriasis Diabetologia 54 2011 2745 2754
64. P.V. Højberg, T. Vilsbøll, R. Rabøl, F.K. Knop, M. Bache, T. Krarup, J.J. Holst, and S. Madsbad Four weeks of near-normalisation of blood glucose improves the insulin response to glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes Diabetologia 52 2009 199 207
65. G.G. Holz 4th, W.M. Kühtreiber, and J.F. Habener Pancreatic beta-cells are rendered glucose-competent by the insulinotropic hormone glucagon-like peptide-1(7-37) Nature 361 1993 362 365
66. J. Jendle, M.A. Nauck, D.R. Matthews, A. Frid, K. Hermansen, M. Düring, M. Zdravkovic, B.J. Strauss, A.J. Garber LEAD-2 and LEAD-3 Study Groups Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue Diabetes Obes. Metab. 11 2009 1163 1172
67. J. Keller, M.E. Trautmann, H. Haber, L.S. Tham, T. Hunt, K. Mace, and H. Linnebjerg Effect of exenatide on cholecystokinin-induced gallbladder emptying in fasting healthy subjects Regul. Pept. 179 2012 77 83
68. U. Kielgast, T. Krarup, J.J. Holst, and S. Madsbad Four weeks of treatment with liraglutide reduces insulin dose without loss of glycemic control in type 1 diabetic patients with and without residual beta-cell function Diabetes Care 34 2011 1463 1468
69. M. Kim, M. Platt, T. Shibasaki, S. Quaggin, P.H. Backx, S. Seino, J. Simpson, and D.J. Drucker GLP-1 receptor activation and Epac2 link atrial natriuretic peptide secretion to control of blood pressure Nat Med. 2013 10.1038/nm.3128 Published online March 31, 2013
70. S. Kim, M. Moon, and S. Park Exendin-4 protects dopaminergic neurons by inhibition of microglial activation and matrix metalloproteinase-3 expression in an animal model of Parkinson's disease J. Endocrinol. 202 2009 431 439
71. A. King, J. Lock, G. Xu, S. Bonner-Weir, and G.C. Weir Islet transplantation outcomes in mice are better with fresh islets and exendin-4 treatment Diabetologia 48 2005 2074 2079
72. D.C. Klonoff, J.B. Buse, L.L. Nielsen, X. Guan, C.L. Bowlus, J.H. Holcombe, M.E. Wintle, and D.G. Maggs Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years Curr. Med. Res. Opin. 24 2008 275 286
73. C. Knauf, P.D. Cani, C. Perrin, M.A. Iglesias, J.F. Maury, E. Bernard, F. Benhamed, T. Grémeaux, D.J. Drucker, and C.R. Kahn Brain glucagon-like peptide-1 increases insulin secretion and muscle insulin resistance to favor hepatic glycogen storage J. Clin. Invest. 115 2005 3554 3563
74. C. Knauf, P.D. Cani, A. Ait-Belgnaoui, A. Benani, C. Dray, C. Cabou, A. Colom, M. Uldry, S. Rastrelli, and E. Sabatier Brain glucagon-like peptide 1 signaling controls the onset of high-fat diet-induced insulin resistance and reduces energy expenditure Endocrinology 149 2008 4768 4777
75. C. Knauf, P.D. Cani, D.H. Kim, M.A. Iglesias, C. Chabo, A. Waget, A. Colom, S. Rastrelli, N.M. Delzenne, and D.J. Drucker Role of central nervous system glucagon-like Peptide-1 receptors in enteric glucose sensing Diabetes 57 2008 2603 2612
76. R. Kodera, K. Shikata, H.U. Kataoka, T. Takatsuka, S. Miyamoto, M. Sasaki, N. Kajitani, S. Nishishita, K. Sarai, and D. Hirota Glucagon-like peptide-1 receptor agonist ameliorates renal injury through its anti-inflammatory action without lowering blood glucose level in a rat model of type 1 diabetes Diabetologia 54 2011 965 978
77. J.A. Koehler, L.L. Baggio, B.J. Lamont, S. Ali, and D.J. Drucker Glucagon-like peptide-1 receptor activation modulates pancreatitis-associated gene expression but does not modify the susceptibility to experimental pancreatitis in mice Diabetes 58 2009 2148 2161
78. J.A. Koehler, T. Kain, and D.J. Drucker Glucagon-like peptide-1 receptor activation inhibits growth and augments apoptosis in murine CT26 colon cancer cells Endocrinology 152 2011 3362 3372
79. M. Körner, M. Stöckli, B. Waser, and J.C. Reubi GLP-1 receptor expression in human tumors and human normal tissues: potential for in vivo targeting J. Nucl. Med. 48 2007 736 743
80. B.J. Lamont, and D.J. Drucker Differential antidiabetic efficacy of incretin agonists versus DPP-4 inhibition in high fat fed mice Diabetes 57 2008 190 198
81. B.J. Lamont, Y. Li, E. Kwan, T.J. Brown, H. Gaisano, and D.J. Drucker Pancreatic GLP-1 receptor activation is sufficient for incretin control of glucose metabolism in mice J. Clin. Invest. 122 2012 388 402
82. Y. Li, T. Perry, M.S. Kindy, B.K. Harvey, D. Tweedie, H.W. Holloway, K. Powers, H. Shen, J.M. Egan, and K. Sambamurti GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism Proc. Natl. Acad. Sci. USA 106 2009 1285 1290
83. Y. Li, S. Chigurupati, H.W. Holloway, M. Mughal, D. Tweedie, D.A. Bruestle, M.P. Mattson, Y. Wang, B.K. Harvey, and B. Ray Exendin-4 ameliorates motor neuron degeneration in cellular and animal models of amyotrophic lateral sclerosis PLoS ONE 7 2012 e32008
84. Z. Liu, and J.F. Habener Glucagon-like peptide-1 activation of TCF7L2-dependent Wnt signaling enhances pancreatic beta cell proliferation J. Biol. Chem. 283 2008 8723 8735
85. S.H. Lockie, K.M. Heppner, N. Chaudhary, J.R. Chabenne, D.A. Morgan, C. Veyrat-Durebex, G. Ananthakrishnan, F. Rohner-Jeanrenaud, D.J. Drucker, and R. DiMarchi Direct control of brown adipose tissue thermogenesis by central nervous system glucagon-like peptide-1 receptor signaling Diabetes 61 2012 2753 2762
86. W.J. Lu, Q. Yang, L. Yang, D. Lee, D. D'Alessio, and P. Tso Chylomicron formation and secretion is required for lipid-stimulated release of incretins GLP-1 and GIP Lipids 47 2012 571 580
87. V. Lyssenko, L. Eliasson, O. Kotova, K. Pilgaard, N. Wierup, A. Salehi, A. Wendt, A. Jonsson, Y.Z. De Marinis, and L.M. Berglund Pleiotropic effects of GIP on islet function involve osteopontin Diabetes 60 2011 2424 2433
88. A. Maida, T. Hansotia, C. Longuet, Y. Seino, and D.J. Drucker Differential importance of glucose-dependent insulinotropic polypeptide vs glucagon-like peptide 1 receptor signaling for beta cell survival in mice Gastroenterology 137 2009 2146 2157
89. A. Maida, B.J. Lamont, X. Cao, and D.J. Drucker Metformin regulates the incretin receptor axis via a pathway dependent on peroxisome proliferator-activated receptor-α in mice Diabetologia 54 2011 339 349
90. P. Marchetti, R. Lupi, M. Bugliani, C.L. Kirkpatrick, G. Sebastiani, F.A. Grieco, S. Del Guerra, V. D'Aleo, S. Piro, and L. Marselli A local glucagon-like peptide 1 (GLP-1) system in human pancreatic islets Diabetologia 55 2012 3262 3272
91. J.E. Mells, P.P. Fu, S. Sharma, D.E. Olson, L. Cheng, J.A. Handy, N.K. Saxena, D. Sorescu, and F.A. Anania Glp-1 analog, liraglutide, ameliorates hepatic steatosis and cardiac hypertrophy in C57BL/6J mice fed a Western diet Am. J. Physiol. Gastrointest. Liver Physiol. 302 2012 G225 G235
92. N. Mentis, I. Vardarli, L.D. Köthe, J.J. Holst, C.F. Deacon, M. Theodorakis, J.J. Meier, and M.A. Nauck GIP does not potentiate the antidiabetic effects of GLP-1 in hyperglycemic patients with type 2 diabetes Diabetes 60 2011 1270 1276
93. E.M. Migoya, R. Bergeron, J.L. Miller, R.N. Snyder, M. Tanen, D. Hilliard, B. Weiss, P. Larson, M. Gutierrez, and G. Jiang Dipeptidyl peptidase-4 inhibitors administered in combination with metformin result in an additive increase in the plasma concentration of active GLP-1 Clin. Pharmacol. Ther. 88 2010 801 808
94. K. Miyawaki, Y. Yamada, H. Yano, H. Niwa, N. Ban, Y. Ihara, A. Kubota, S. Fujimoto, M. Kajikawa, and A. Kuroe Glucose intolerance caused by a defect in the entero-insular axis: a study in gastric inhibitory polypeptide receptor knockout mice Proc. Natl. Acad. Sci. USA 96 1999 14843 14847
95. K. Miyawaki, Y. Yamada, N. Ban, Y. Ihara, K. Tsukiyama, H. Zhou, S. Fujimoto, A. Oku, K. Tsuda, and S. Toyokuni Inhibition of gastric inhibitory polypeptide signaling prevents obesity Nat. Med. 8 2002 738 742
96. J.S. Nachnani, D.G. Bulchandani, A. Nookala, B. Herndon, A. Molteni, P. Pandya, R. Taylor, T. Quinn, L. Weide, and L.M. Alba Biochemical and histological effects of exendin-4 (exenatide) on the rat pancreas Diabetologia 53 2010 153 159
97. R. Nogueiras, D. Pérez-Tilve, C. Veyrat-Durebex, D.A. Morgan, L. Varela, W.G. Haynes, J.T. Patterson, E. Disse, P.T. Pfluger, and M. López Direct control of peripheral lipid deposition by CNS GLP-1 receptor signaling is mediated by the sympathetic nervous system and blunted in diet-induced obesity J. Neurosci. 29 2009 5916 5925
98. M.H. Noyan-Ashraf, M.A. Momen, K. Ban, A.M. Sadi, Y.Q. Zhou, A.M. Riazi, L.L. Baggio, R.M. Henkelman, M. Husain, and D.J. Drucker GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice Diabetes 58 2009 975 983
99. J. Nyberg, M.F. Anderson, B. Meister, A.M. Alborn, A.K. Ström, A. Brederlau, A.C. Illerskog, O. Nilsson, T.J. Kieffer, and M.A. Hietala Glucose-dependent insulinotropic polypeptide is expressed in adult hippocampus and induces progenitor cell proliferation J. Neurosci. 25 2005 1816 1825
100. J. Nyberg, C. Jacobsson, M.F. Anderson, and P.S. Eriksson Immunohistochemical distribution of glucose-dependent insulinotropic polypeptide in the adult rat brain J. Neurosci. Res. 85 2007 2099 2119
101. N. Panjwani, E.E. Mulvihill, C. Longuet, B. Yusta, J.E. Campbell, T.J. Brown, C. Streutker, D. Holland, X. Cao, L.L. Baggio, and D.J. Drucker GLP-1 receptor activation indirectly reduces hepatic lipid accumulation but does not attenuate development of atherosclerosis in diabetic male ApoE(-/-) mice Endocrinology 154 2013 127 139
102. T. Perry, D.K. Lahiri, K. Sambamurti, D. Chen, M.P. Mattson, J.M. Egan, and N.H. Greig Glucagon-like peptide-1 decreases endogenous amyloid-beta peptide (Abeta) levels and protects hippocampal neurons from death induced by Abeta and iron J. Neurosci. Res. 72 2003 603 612
103. K. Pilgaard, C.B. Jensen, J.H. Schou, V. Lyssenko, L. Wegner, C. Brøns, T. Vilsbøll, T. Hansen, S. Madsbad, and J.J. Holst The T allele of rs7903146 TCF7L2 is associated with impaired insulinotropic action of incretin hormones, reduced 24 h profiles of plasma insulin and glucagon, and increased hepatic glucose production in young healthy men Diabetologia 52 2009 1298 1307
104. A. Pocai, P.E. Carrington, J.R. Adams, M. Wright, G. Eiermann, L. Zhu, X. Du, A. Petrov, M.E. Lassman, and G. Jiang Glucagon-like peptide 1/glucagon receptor dual agonism reverses obesity in mice Diabetes 58 2009 2258 2266
105. U. Pugazhenthi, K. Velmurugan, A. Tran, G. Mahaffey, and S. Pugazhenthi Anti-inflammatory action of exendin-4 in human islets is enhanced by phosphodiesterase inhibitors: potential therapeutic benefits in diabetic patients Diabetologia 53 2010 2357 2368
106. C. Pyke, and L.B. Knudsen The glucagon-like peptide-1 receptor - or not? Endocrinology 154 2013 4 8
107. J. Quoyer, C. Longuet, C. Broca, N. Linck, S. Costes, E. Varin, J. Bockaert, G. Bertrand, and S. Dalle GLP-1 mediates antiapoptotic effect by phosphorylating Bad through a beta-arrestin 1-mediated ERK1/2 activation in pancreatic beta-cells J. Biol. Chem. 285 2010 1989 2002
108. M.M. Rankin, and J.A. Kushner Adaptive beta-cell proliferation is severely restricted with advanced age Diabetes 58 2009 1365 1372
109. F. Reimann, G. Tolhurst, and F.M. Gribble G-protein-coupled receptors in intestinal chemosensation Cell Metab. 15 2012 421 431
110. J.C. Reubi, A. Perren, R. Rehmann, B. Waser, E. Christ, M. Callery, A.B. Goldfine, and M.E. Patti Glucagon-like peptide-1 (GLP-1) receptors are not overexpressed in pancreatic islets from patients with severe hyperinsulinaemic hypoglycaemia following gastric bypass Diabetologia 53 2010 2641 2645
111. M.R. Rickels, R. Mueller, J.F. Markmann, and A. Naji Effect of glucagon-like peptide-1 on beta- and alpha-cell function in isolated islet and whole pancreas transplant recipients J. Clin. Endocrinol. Metab. 94 2009 181 189
112. T. Rieg, M. Gerasimova, F. Murray, T. Masuda, T. Tang, M. Rose, D.J. Drucker, and V. Vallon Natriuretic effect by exendin-4, but not the DPP-4 inhibitor alogliptin, is mediated via the GLP-1 receptor and preserved in obese type 2 diabetic mice Am. J. Physiol. Renal Physiol. 303 2012 F963 F971
113. K.I. Rother, L.M. Spain, R.A. Wesley, B.J. Digon 3rd, A. Baron, K. Chen, P. Nelson, H.M. Dosch, J.P. Palmer, and B. Brooks-Worrell Effects of exenatide alone and in combination with daclizumab on beta-cell function in long-standing type 1 diabetes Diabetes Care 32 2009 2251 2257
114. M. Salehi, R.L. Prigeon, and D.A. D'Alessio Gastric bypass surgery enhances glucagon-like peptide 1-stimulated postprandial insulin secretion in humans Diabetes 60 2011 2308 2314
115. D.A. Sandoval, D. Bagnol, S.C. Woods, D.A. D'Alessio, and R.J. Seeley Arcuate glucagon-like peptide 1 receptors regulate glucose homeostasis but not food intake Diabetes 57 2008 2046 2054
116. P. Sathyanarayana, M. Jogi, R. Muthupillai, R. Krishnamurthy, S.L. Samson, and M. Bajaj Effects of combined exenatide and pioglitazone therapy on hepatic fat content in type 2 diabetes Obesity (Silver Spring) 19 2011 2310 2315
117. R. Saxena, M.F. Hivert, C. Langenberg, T. Tanaka, J.S. Pankow, P. Vollenweider, V. Lyssenko, N. Bouatia-Naji, J. Dupuis, A.U. Jackson GIANT consortium; MAGIC investigators Genetic variation in GIPR influences the glucose and insulin responses to an oral glucose challenge Nat. Genet. 42 2010 142 148
118. S.A. Schäfer, O. Tschritter, F. Machicao, C. Thamer, N. Stefan, B. Gallwitz, J.J. Holst, J.M. Dekker, L.M. 't Hart, and G. Nijpels Impaired glucagon-like peptide-1-induced insulin secretion in carriers of transcription factor 7-like 2 (TCF7L2) gene polymorphisms Diabetologia 50 2007 2443 2450
119. M. Seghieri, E. Rebelos, A. Gastaldelli, B.D. Astiarraga, A. Casolaro, E. Barsotti, A. Pocai, M. Nauck, E. Muscelli, and E. Ferrannini Direct effect of GLP-1 infusion on endogenous glucose production in humans Diabetologia 56 2013 156 161
120. Y.K. Shin, B. Martin, E. Golden, C.D. Dotson, S. Maudsley, W. Kim, H.J. Jang, M.P. Mattson, D.J. Drucker, J.M. Egan, and S.D. Munger Modulation of taste sensitivity by GLP-1 signaling J. Neurochem. 106 2008 455 463
121. A. Shiraki, J. Oyama, H. Komoda, M. Asaka, A. Komatsu, M. Sakuma, K. Kodama, Y. Sakamoto, N. Kotooka, T. Hirase, and K. Node The glucagon-like peptide 1 analog liraglutide reduces TNF-α-induced oxidative stress and inflammation in endothelial cells Atherosclerosis 221 2012 375 382
122. L. Shu, A.V. Matveyenko, J. Kerr-Conte, J.H. Cho, C.H. McIntosh, and K. Maedler Decreased TCF7L2 protein levels in type 2 diabetes mellitus correlate with downregulation of GIP- and GLP-1 receptors and impaired beta-cell function Hum. Mol. Genet. 18 2009 2388 2399
123. L. Simonsen, S. Pilgaard, C. Orskov, M.M. Rosenkilde, B. Hartmann, J.J. Holst, and C.F. Deacon Exendin-4, but not dipeptidyl peptidase IV inhibition, increases small intestinal mass in GK rats Am. J. Physiol. Gastrointest. Liver Physiol. 293 2007 G288 G295
124. G. Smushkin, M. Sathananthan, A. Sathananthan, C. Dalla Man, F. Micheletto, A.R. Zinsmeister, C. Cobelli, and A. Vella Diabetes-associated common genetic variation and its association with GLP-1 concentrations and response to exogenous GLP-1 Diabetes 61 2012 1082 1089
125. N. Sonoda, T. Imamura, T. Yoshizaki, J.L. Babendure, J.C. Lu, and J.M. Olefsky Beta-Arrestin-1 mediates glucagon-like peptide-1 signaling to insulin secretion in cultured pancreatic beta cells Proc. Natl. Acad. Sci. USA 105 2008 6614 6619
126. W.L. Suarez-Pinzon, R.F. Power, Y. Yan, C. Wasserfall, M. Atkinson, and A. Rabinovitch Combination therapy with glucagon-like peptide-1 and gastrin restores normoglycemia in diabetic NOD mice Diabetes 57 2008 3281 3288
127. K. Suzuki, N. Harada, S. Yamane, Y. Nakamura, K. Sasaki, D. Nasteska, E. Joo, K. Shibue, T. Harada, and A. Hamasaki Transcriptional regulatory factor X6 (Rfx6) increases gastric inhibitory polypeptide (GIP) expression in enteroendocrine K-cells and is involved in GIP hypersecretion in high fat diet-induced obesity J. Biol. Chem. 288 2013 1929 1938
128. G. Svegliati-Baroni, S. Saccomanno, C. Rychlicki, L. Agostinelli, S. De Minicis, C. Candelaresi, G. Faraci, D. Pacetti, M. Vivarelli, and D. Nicolini Glucagon-like peptide-1 receptor activation stimulates hepatic lipid oxidation and restores hepatic signalling alteration induced by a high-fat diet in nonalcoholic steatohepatitis Liver Int. 31 2011 1285 1297
129. K. Tatarkiewicz, P.A. Smith, E.J. Sablan, C.J. Polizzi, D.E. Aumann, C. Villescaz, D.M. Hargrove, B.R. Gedulin, M.G. Lu, and L. Adams Exenatide does not
130. S. Teramoto, N. Miyamoto, K. Yatomi, Y. Tanaka, H. Oishi, H. Arai, N. Hattori, and T. Urabe Exendin-4, a glucagon-like peptide-1 receptor agonist, provides neuroprotection in mice transient focal cerebral ischemia J. Cereb. Blood Flow Metab. 31 2011 1696 1705
131. L. Tian, J. Gao, G. Weng, H. Yi, B. Tian, T.D. O'Brien, and Z. Guo Comparison of exendin-4 on beta-cell replication in mouse and human islet grafts Transpl. Int. 24 2011 856 864
132. J.L. Trevaskis, P.S. Griffin, C. Wittmer, B.A. Neuschwander-Tetri, E.M. Brunt, C.S. Dolman, M.R. Erickson, J. Napora, D.G. Parkes, and J.D. Roth Glucagon-like peptide-1 receptor agonism improves metabolic, biochemical, and histopathological indices of nonalcoholic steatohepatitis in mice Am. J. Physiol. Gastrointest. Liver Physiol. 302 2012 G762 G772
133. S.I. Tschen, S. Dhawan, T. Gurlo, and A. Bhushan Age-dependent decline in beta-cell proliferation restricts the capacity of beta-cell regeneration in mice Diabetes 58 2009 1312 1320
134. S.I. Tschen, S. Georgia, S. Dhawan, and A. Bhushan Skp2 is required for incretin hormone-mediated β-cell proliferation Mol. Endocrinol. 25 2011 2134 2143
135. M.H. Tschöp, and R.D. DiMarchi Outstanding Scientific Achievement Award Lecture 2011: defeating diabesity: the case for personalized combinatorial therapies Diabetes 61 2012 1309 1314
136. K. Tsukiyama, Y. Yamada, C. Yamada, N. Harada, Y. Kawasaki, M. Ogura, K. Bessho, M. Li, N. Amizuka, and M. Sato Gastric inhibitory polypeptide as an endogenous factor promoting new bone formation after food ingestion Mol. Endocrinol. 20 2006 1644 1651
137. R. Ugleholdt, J. Pedersen, M.R. Bassi, E.M. Füchtbauer, S.M. Jørgensen, H.L. Kissow, N. Nytofte, S.S. Poulsen, M.M. Rosenkilde, and Y. Seino Transgenic rescue of adipocyte glucose-dependent insulinotropic polypeptide receptor expression restores high fat diet-induced body weight gain J. Biol. Chem. 286 2011 44632 44645
138. J.R. Ussher, and D.J. Drucker Cardiovascular biology of the incretin system Endocr. Rev. 33 2012 187 215
139. T.P. Vahl, M. Tauchi, T.S. Durler, E.E. Elfers, T.M. Fernandes, R.D. Bitner, K.S. Ellis, S.C. Woods, R.J. Seeley, J.P. Herman, and D.A. D'Alessio Glucagon-like peptide-1 (GLP-1) receptors expressed on nerve terminals in the portal vein mediate the effects of endogenous GLP-1 on glucose tolerance in rats Endocrinology 148 2007 4965 4973
140. J. Vendrell, R. El Bekay, B. Peral, E. García-Fuentes, A. Megia, M. Macias-Gonzalez, J. Fernández Real, Y. Jimenez-Gomez, X. Escoté, and G. Pachón Study of the potential association of adipose tissue GLP-1 receptor with obesity and insulin resistance Endocrinology 152 2011 4072 4079
141. D.T. Villareal, H. Robertson, G.I. Bell, B.W. Patterson, H. Tran, B. Wice, and K.S. Polonsky TCF7L2 variant rs7903146 affects the risk of type 2 diabetes by modulating incretin action Diabetes 59 2010 479 485
142. A. Waget, C. Cabou, M. Masseboeuf, P. Cattan, M. Armanet, M. Karaca, J. Castel, C. Garret, G. Payros, and A. Maida Physiological and pharmacological mechanisms through which the DPP-4 inhibitor sitagliptin regulates glycemia in mice Endocrinology 152 2011 3018 3029
143. B.M. Wice, S. Wang, D.L. Crimmins, K.A. Diggs-Andrews, M.C. Althage, E.L. Ford, H. Tran, M. Ohlendorf, T.A. Griest, and Q. Wang Xenin-25 potentiates glucose-dependent insulinotropic polypeptide action via a novel cholinergic relay mechanism J. Biol. Chem. 285 2010 19842 19853
144. B.M. Wice, D.N. Reeds, H.D. Tran, D.L. Crimmins, B.W. Patterson, J. Dunai, M.J. Wallendorf, J.H. Ladenson, D.T. Villareal, and K.S. Polonsky Xenin-25 amplifies GIP-mediated insulin secretion in humans with normal and impaired glucose tolerance but not type 2 diabetes Diabetes 61 2012 1793 1800
145. S.B. Widenmaier, Z. Ao, S.J. Kim, G. Warnock, and C.H. McIntosh Suppression of p38 MAPK and JNK via Akt-mediated inhibition of apoptosis signal-regulating kinase 1 constitutes a core component of the beta-cell pro-survival effects of glucose-dependent insulinotropic polypeptide J. Biol. Chem. 284 2009 30372 30382
146. H.E. Wilson-Pérez, A.P. Chambers, K.K. Ryan, B. Li, D.A. Sandoval, D. Stoffers, D.J. Drucker, D. Pérez-Tilve, and R.J. Seeley Vertical sleeve gastrectomy is effective in two genetic mouse models of glucagon-like peptide-1 receptor deficiency Diabetes 2013 10.2337/db12-149 Published online February 22, 2013
147. G. Xu, H. Kaneto, D.R. Laybutt, V.F. Duvivier-Kali, N. Trivedi, K. Suzuma, G.L. King, G.C. Weir, and S. Bonner-Weir Downregulation of GLP-1 and GIP receptor expression by hyperglycemia: possible contribution to impaired incretin effects in diabetes Diabetes 56 2007 1551 1558
148. C. Yamada, Y. Yamada, K. Tsukiyama, K. Yamada, N. Udagawa, N. Takahashi, K. Tanaka, D.J. Drucker, Y. Seino, and N. Inagaki The murine glucagon-like peptide-1 receptor is essential for control of bone resorption Endocrinology 149 2008 574 579
149. F. Yi, P.L. Brubaker, and T. Jin TCF-4 mediates cell type-specific regulation of proglucagon gene expression by beta-catenin and glycogen synthase kinase-3beta J. Biol. Chem. 280 2005 1457 1464
150. J. Zhang, Y. Tokui, K. Yamagata, J. Kozawa, K. Sayama, H. Iwahashi, K. Okita, M. Miuchi, H. Konya, and T. Hamaguchi Continuous stimulation of human glucagon-like peptide-1 (7-36) amide in a mouse model (NOD) delays onset of autoimmune type 1 diabetes Diabetologia 50 2007 1900 1909